Skip to main content

COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy

Publication ,  Conference
Daughety, M; Ortel, TL; Frost, E; Morgan, A; Kao, C; Hwang, J; Patel, B; Welsby, IJ
Published in: Blood
November 5, 2020

Introduction: Early studies identified a prothrombotic state associated with novel coronavirus disease 2019 (COVID-19) as well as a survival benefit observed with heparin use in severely ill COVID-19 patients. There is a need to clarify the incidence of thromboembolic events (TEs), as well as major hemorrhage in COVID-19 patients in the context of an escalated-dose thromboprophylaxis strategy.Methods: We conducted a single center, retrospective study of 192 consecutive patients with COVID-19 admitted to the hospital between March 26th and May 8th 2020. Our study aimed to investigate the rates of thromboembolic events (TEs), hemorrhage and mortality of in the context of an escalated-dose thromboprophylaxis strategy implemented early in our experience with hospitalized patients with COVID-19.Results: The incidence of radiographically-confirmed venous thromboembolism (VTE) was 7.3% (n=14), and the rate of combined TEs was 12% (n=23). The rate of major hemorrhage was 6.3% (n=12), including one fatal CNS bleed. The overall mortality rate was 27.6% (n=53).Conclusion: The rate of VTE and overall TE was much lower than was reported in early studies, and the majority of VTEs occurred in ambulatory patients. Our data suggest that an escalated-dose thromboprophylaxis strategy may help reduce the incidence of inpatient VTEs, and that ambulatory COVID-19 patients may benefit from primary thromboprophylaxis. However, the risk of bleeding was not negligible, and must therefore be assessed on an individual and continual basis when using a more aggressive thromboprophylaxis strategy.

Duke Scholars

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 5, 2020

Volume

136

Issue

Supplement 1

Start / End Page

23 / 24

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Daughety, M., Ortel, T. L., Frost, E., Morgan, A., Kao, C., Hwang, J., … Welsby, I. J. (2020). COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy. In Blood (Vol. 136, pp. 23–24). American Society of Hematology. https://doi.org/10.1182/blood-2020-142944
Daughety, Molly, Thomas L. Ortel, Erin Frost, Andrew Morgan, Chester Kao, Joyce Hwang, Bhavik Patel, and Ian J. Welsby. “COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy.” In Blood, 136:23–24. American Society of Hematology, 2020. https://doi.org/10.1182/blood-2020-142944.
Daughety M, Ortel TL, Frost E, Morgan A, Kao C, Hwang J, et al. COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy. In: Blood. American Society of Hematology; 2020. p. 23–4.
Daughety, Molly, et al. “COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy.” Blood, vol. 136, no. Supplement 1, American Society of Hematology, 2020, pp. 23–24. Crossref, doi:10.1182/blood-2020-142944.
Daughety M, Ortel TL, Frost E, Morgan A, Kao C, Hwang J, Patel B, Welsby IJ. COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy. Blood. American Society of Hematology; 2020. p. 23–24.

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 5, 2020

Volume

136

Issue

Supplement 1

Start / End Page

23 / 24

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology